OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
The OncLive Insider app is live!CME Opportunities
Specialty
View MoreBreast CancerLung CancerGastrointestinal CancerGenitourinary CancersOvarian CancerProstate CancerMelanoma & Skin CancerMCLMPNCAR T-cell TherapyChronic Lymphocytic LeukemiaGynecologic OncologyHematologic OncologyImmuno-OncologyMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
PartnersPublications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker ConsortiumSubscribe
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • The OncLive Insider app is live!
  • CME Opportunities
SpecialtySee All >
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Ovarian Cancer
  • Prostate Cancer
  • Melanoma & Skin Cancer
  • MCL
  • MPN
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gynecologic Oncology
  • Hematologic Oncology
  • Immuno-Oncology
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Christopher Twelves, MD

  1. home

Articles

Dr. Twelves Highlights Findings From the 2012 SABCS

February 21st 2013

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Dr. Twelves Compares Eribulin and Capecitabine

December 8th 2012

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

Dr. Twelves on the Value of the Iniparib Trial Results

April 1st 2011

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Dr. Twelves on Negative Phase III Iniparib Announcements

April 1st 2011

Dr. Twelves Describes Iniparib Clinical Trials

April 1st 2011